ISRIB

ISRIB, short for integrated stress response inhibitor, is a synthetic, drug-like small molecule discovered in 2013 by a team at the University of California, San Francisco. It emerged from a cell-based screen for inhibitors of PERK signaling, one arm of a network of stress pathways collectively known as the integrated stress response (ISR) ^[1]. Chemically it is a symmetric bis-glycolamide, and it is notable for being one of the first molecules able to switch off the ISR pharmacologically.

The integrated stress response is a conserved cellular program: in response to stresses such as viral infection, endoplasmic reticulum stress, or nutrient deprivation, one of several kinases (PERK, PKR, GCN2, or HRI) phosphorylates the alpha subunit of translation initiation factor eIF2. This phosphorylation converts eIF2 from a substrate into a competitive inhibitor of eIF2B, its guanine nucleotide exchange factor, which broadly dampens protein synthesis while allowing preferential translation of certain stress mRNAs. ISRIB targets eIF2B directly and reverses these effects, restoring translation even when eIF2 is phosphorylated ^[1][2]. Structural studies using cryo-electron microscopy showed that ISRIB binds in a deep cleft at the center of the decameric eIF2B complex, acting as a molecular staple that cross-bridges two tetrameric halves to stabilize the fully active enzyme ^[3][5].

Because eIF2 phosphorylation limits memory consolidation, releasing this brake has striking cognitive effects: ISRIB-treated mice show enhanced spatial and fear-associated learning, and the molecule corrects cognitive deficits after traumatic brain injury and in models of neurodegeneration and Alzheimer's-related amyloid toxicity ^[1][3][6]. A distinctive safety-relevant feature is that ISRIB only suppresses low-level ISR activation and loses effect once eIF2 phosphorylation exceeds a threshold, which may explain its lack of overt toxicity in animals ^[4]. ISRIB is an investigational research compound and is not an approved medicine.

Human safety: entirely unknown. Zero human exposures on record, no adverse-event data, no maximum tolerated dose, no drug-interaction data, no reproductive, genotoxicity or carcinogenicity testing, and no published toxicology package of any kind for ISRIB.

Animal safety: thin and short-term. Sidrauski 2013 (PMID 23741617) reported "no overt toxicity" in mice over the brief courses used, and later behavioural papers do not report tolerability outcomes at all; Chou 2017 (PMID 28696288), for instance, reports no weight, toxicity or side-effect data. No chronic-dosing study of ISRIB in any species was found. "No overt toxicity over three injections in a mouse" is not a safety record.

Mechanism-based hazards that are actually documented, not speculative: 1. The integrated stress response is protective. Sidrauski 2013 showed ISRIB reduces the viability of cells undergoing PERK activation by chronic ER stress, and that unmitigated ER stress synergises with ISRIB to drive apoptosis. Suppressing an adaptive alarm is the core risk of this whole drug class. 2. ISRIB is self-limiting, which cuts both ways. Rabouw 2019 (PMID 30674674) showed ISRIB cannot suppress the ISR once phosphorylated eIF2-alpha rises above a threshold; the authors propose this is exactly why ISRIB does not produce overt toxicity in vivo. The same property caps how much it can ever do. 3. Direction of effect in cancer cells is context dependent, not uniformly benign: ISRIB protected multiple myeloma cells from bortezomib-induced apoptosis while sensitising breast cancer cells to it (PMID 35114585). 4. Theoretical and untested in humans: the ISR is part of antiviral and innate immune defence and of pancreatic beta-cell adaptation, so long-term suppression is a plausible risk that no study has addressed.

Interactions: none characterised. No CYP, transporter or clinical drug-drug interaction data exists for ISRIB.

Regulatory status: not approved by any regulator, anywhere, for any indication, in any species. ISRIB is sold only as a "research use only, not for human consumption" laboratory reagent (Cayman Chemical, Sigma-Aldrich, Santa Cruz Biotechnology and others; CAS 1597403-47-8), and it circulates in the nootropics community through grey-market group buys. It is not a scheduled controlled substance in the US.

WADA: ISRIB is not named on the WADA Prohibited List. It falls squarely inside the S0 "Non-Approved Substances" definition, which prohibits at all times any pharmacological substance not currently approved by any governmental regulatory health authority for human therapeutic use. An athlete should treat ISRIB as banned in and out of competition.

Bearing on the mechanism, though not on ISRIB itself: the two eIF2B activators that did reach humans have not delivered. Denali's DNL343 missed the primary endpoint and showed no neurofilament-light effect in HEALEY ALS Regimen G, and the extension was discontinued in March 2025, although the drug was reported safe and well tolerated. AbbVie/Calico's fosigotifator (ABBV-CLS-7262) has a Phase 1 ALS study and a Phase 1b major depressive disorder study both listed as TERMINATED on ClinicalTrials.gov, with vanishing white matter disease trials still running.

ISRIB was discovered in 2013 at the University of California, San Francisco in the laboratory of Peter Walter, identified in a phenotypic screen for small molecules that block the integrated stress response. Its molecular target was subsequently mapped to eIF2B, and cryo-electron microscopy revealed that it binds within the central cleft of the eIF2B decamer, acting as a molecular staple that stabilizes the active enzyme. Since its discovery it has become one of the most studied experimental neuroprotective and memory-enhancing molecules, with reports of enhanced cognition in healthy mice and correction of deficits after traumatic brain injury. It remains a research compound, and it has inspired clinical-stage derivatives.

ISRIB is widely celebrated in neuroscience as a proof of concept that a single small molecule can lift a brake on protein synthesis and, in doing so, sharpen memory in animals. It is admired for its precision; it reactivates eIF2B only below a threshold of stress, leaving the protective acute stress response intact, which likely explains its clean tolerability in rodent studies. Findings that it can reverse traumatic brain injury deficits and normalize memory in Alzheimer's models have kept it at the frontier of cognitive-aging research. In honest terms, the human evidence is not yet established, and its benefits have been demonstrated primarily in mice and rats.